Programmed death-ligand 1 (PD-L1) is a well-known biomarker for predicting immunotherapy responses; however, its prognostic significance in early-stage NSCLC treated with SBRT remains unclear. The gene discussed is CD274; the disease is non-small cell lung carcinoma.